Bristol Myers Squibb stock: New cancer trial with Erasca
Published on 11/21/2026 at 10:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline Collaboration Adds Oncology Focus
- Bristol Myers Squibb will sponsor a Phase 1/2 study combining navlimetostat with Erasca's ERAS-0015 in MTAP-deleted pancreatic cancer.
- The partners will retain development and commercial rights to their respective compounds under the non-exclusive agreement.
Bristol Myers Squibb and Erasca agreed on November 17, 2026, to evaluate Erasca's ERAS-0015 with BMS's investigational PRMT5 inhibitor navlimetostat in a Phase 1/2 study targeting MTAP-deleted pancreatic ductal adenocarcinoma. Erasca said Bristol Myers Squibb will sponsor the trial, while Erasca will supply ERAS-0015.
Two Experimental Mechanisms Combined
The study brings together ERAS-0015, an investigational pan-RAS molecular glue, and navlimetostat, an investigational PRMT5 inhibitor. The combination is intended for patients whose pancreatic tumors have MTAP deletions, a setting in which the companies see a rationale for simultaneous RAS and PRMT5 inhibition.
The agreement is mutually non-exclusive. Each company will retain development and commercial rights to its own compound. Erasca said the collaboration builds on early clinical activity for ERAS-0015, while the BMS compound remains in clinical development.
Pipeline Milestone Shapes Investor View
The collaboration adds an external program to Bristol Myers Squibb's oncology pipeline and creates a defined clinical development path for the combination. The study remains an investigational step, so its commercial significance will depend on trial execution and future clinical results.
Bristol Myers Squibb stock traded at 53.72 euros on Lang & Schwarz at 10:34 CET on Saturday, November 21, 2026.
Bristol Myers Squibb at a Glance
- Company: Bristol Myers Squibb
- ISIN: US1101221083
- NYSE ticker: BMY
- Latest Lang & Schwarz quote: 53.72 euros on November 21, 2026, at 10:34 CET
Healthcare investors are also tracking developments across the broader US equity market. Current market reports provide the wider market context.
